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Abstract
Background: Podoplanin, a mucin-like transmembrane glycoprotein, is reportedly expressed in a variety of
malignant cells and is generally regarded as a factor for promoting tumor progression in conventional studies. By
contrast, a clinicopathologically conflicting role for podoplanin, namely as a favorable prognostic factor for patients
with lung/cervical squamous cell carcinoma (SCC), has recently been reported. Here, we investigated the role of
podoplanin expressed in lung squamoid cancer cells (LSCCs) in experimental tumor progression.
Results: Using EBC-1 cells, a lung SCC cell line without podoplanin expression and with lymphogenous metastatic
potential, stable transformants with or without an exogenous human podoplanin gene were established and
applied to a mouse tumor implantation model. In vivo examinations revealed that exogenous podoplanin had no
influence on tumor growth, whereas it significantly restrained axillary lymph node metastasis associated with the
suppression of lymphangiogenesis but not angiogenesis and with the downregulation of EBC-1-derived VEGF-C
but not other lymphangiogenesis-related factor mRNAs in implanted tumor tissue. In vitro examinations to clarify
the mechanisms underlying the in vivo phenomena revealed that exogenous podoplanin significantly suppressed
the expression of VEGF-C mRNA and of the protein, and also increased the level of phosphorylated c-jun N
terminal kinase (JNK) in EBC-1 cells. The former effect of exogenous podoplanin was impaired by treatment with
either JNK inhibitor sp600125 or podoplanin-siRNA, and the latter effect was impaired by treatment with
podoplanin-siRNA, suggesting that podoplanin was able to activate JNK, thereby downregulating VEGF-C gene
expression in LSCCs (podoplanin-JNK-VEGF-C axis). Furthermore, supporting evidence in regard to the axis present
in LSCCs was obtained from similar experiments using H157 cells, another lung SCC cell line expressing
endogenous podoplanin.
Conclusions: Our findings suggested that LSCC-associated podoplanin was functional and could attenuate the
potential for lymph node metastasis, possibly based on the suppression of tumor lymphangiogenesis; thus,
podoplanin in cancer cells may become a useful biomarker to measure the malignancy of lung SCC.
Background
Lymphogenous and hematogenous metastases are major
events in malignant tumor progression and important
prognostic determinants of patients with cancer. Metas-
tasis of cancer cells is a multi-step process, including
malignant cell growth, cell detachment, invasion into
adjacent tissue, blood or lymphatic permeation, entry
into the blood or lymph flow, arrival at remote organ or
lymph node, capillary arrest, extravasation, and prolif-
eration within target organs [1]. Numerous factors
expressed in tumor cells are implicated in the process of
metastasis.
Lymph node status is one of the critical prognostic
indicators in patients with malignant tumors, and
tumor-associated lymphangiogenesis is thought to be a
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malignant cells. A number of experimental and clinico-
pathological studies have supported the significance of
lymphangiogenesis in tumor progression, including non-
small cell lung carcinoma [2-5]. Tumor lymphangiogen-
esis is regulated by lymphangiogenesis-related growth
factors expressed in malignant cells and cognate recep-
tors expressed in host lymphatic vessels [6-17]. Espe-
cially, paracrine interaction between vascular endothelial
growth factors (VEGF)-C and -D, and their cognate
receptor, VEGF receptor-3, plays a central role in tumor
lymphangiogenesis in a variety of malignancies [4]. In
many cases, a high expression level of VEGF-C in malig-
nant tumor cells correlates with increased density of
peritumoral lymphatic vessels, increased incidence of
lymph node metastasis, and poor prognosis [17].
Podoplanin is a mucin-like transmembrane glycopro-
tein [18]. Since its expression is completely restricted in
lymphatic endothelial cells in the vascular system, it is
now available as a useful marker to distinguish lympha-
tic vessels immunohistochemically from blood vessels
[19,20]. Podoplanin is also expressed in a variety of non-
neoplastic cells such as podocytes and alveolar type-I
cells [18-23]. According to a recent gene targeting
study, podoplanin
-/- mice showed systemic edema due
to aplastic lymphatic vessels during fetal development,
and neonatal death due to respiratory failure [24,25].
These findings are suggestive of the multi-physiological
functioning of podoplanin in a cell-type-specific manner.
Recently, podoplanin has been reported to be
expressed in a variety of malignant tumor cells, such as
squamous cell carcinoma, methothelioma, and germ cell
tumors [22,26], and evidence suggesting the involvement
of podoplanin in malignant potential from various stu-
dies has accumulated: 1) Podoplanin can alter cell mor-
phology and motility, by which tumor invasive/
migratory activity is promoted [27,28]; 2) Podoplanin
can induce the epithelial-mesenchymal transition [29];
and 3) Podoplanin can induce platelet activation/aggre-
gation mediated by its platelet aggregation-stimulating
(PLAG) domain, resulting in a greater ability to achieve
hematogenous metastasis of circulating tumor cells
[30-32]. Together, previous in vitro and in vivo experi-
mental studies have suggested that podoplanin is an
enhancer that promotes tumor progression
The role of podoplanin in tumor cells, however, seems
to be controversial in recent clinicopathological studies
of human cancers. For example, Yuan et al. and Chuang
et al. demonstrated that a higher expression level of
podoplanin in cancer cells significantly correlated with
poor prognosis and a higher incidence of lymph node
metastasis in head and neck SCC [33,34]. Conversely,
current several reports demonstrate that a lower expres-
sion level of podoplanin in cancer cells significantly
correlated with a poor prognosis and a higher incidence
of lymph node metastasis in both lung and cervical
SCCs [35-37]. Hitherto-existing evidence relating to
podoplanin functions can not explain the mechanism
underlying the tumor suppression. The inconsistent and
elusive results of these traditional experimental and clin-
icopathological studies may s u g g e s tt h a tp o d o p l a n i n
exerts context-dependent multi-functions in different
organ environments and/or different malignant cells,
and that it may act as an enhancer in some cases and a
suppressor in others in tumor progression.
Here, we investigated the role of cancer cell-associated
podoplanin in the progression of lung SCC using an ani-
mal model, and found novel functions of podoplanin as
a suppressor for cancer progression.
Results
Podoplanin does not affect activities of cell growth and
migration in vitro
First, we examined the expression level of podoplanin in a
variety of lung SCC cell lines. RT-PCR revealed that only
EBC-1 cells showed no podoplanin expression (Figure
1A). This finding was confirmed by real-time PCR (data
not shown). In addition, 21 days after cutaneous inocula-
tion of EBC-1 cells in the dorsal area of BALB/c nu/nu
mice, approximate 65% mice showed axillary lymph node
metastasis, suggesting that EBC-1 cells possessed high
lymphogenous metastatic potential and were available for
validating the effect of podoplanin in lymphogenous
metastasis. Then, EBC-1 cell-derived stable transformants
with or without cDNA of human podoplanin were estab-
lished. Eventually, 15 single clones were established, and
the two of these (EBC1-Ps: EBC1-P4 and EBC1-P15) that
had the highest expression of podoplanin mRNA were
adopted (data not shown). On the contrary, 3 single clones
with empty vectors were simultaneously established and
two clones (EBC-Vs: EBC1-V1 and EBC1-V2) were ran-
domly adopted as controls. Protein expression of exogen-
ous podoplanin was confirmed by Western blot analysis
(Figure 1B). These clones were used in a series of experi-
ments in this study. Using these stable transformants, we
examined the effects of podoplanin on EBC-1 migration
and proliferation activities. As a result, podoplanin had no
influence on the proliferation and migration of EBC-1
cells in vitro as evidenced by Figures 1C and 1D. Regard-
ing the negative data obtained from the migration assay,
we performed additional experiments to indicate a positive
control, which revealed that stable overexpression of exo-
genous podoplanin could promote the migration activity
in SAS cells, an oral SCC cell line (additional file 1). This
finding strongly suggested that podoplanin had no influ-
ence on the migration activity of LSCCs in vitro.M o r e -
over, no apparent changes in cell morphology, such as
filopodia-like formation, could be observed in EBC1-Ps
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Page 2 of 15Figure 1 Effect of podoplanin expression in tumor cells on cellular function in vitro. A) RT-PCR for human podoplanin and GAPDH was
performed with cDNA from LSCC cell lines QG56, H157, and EBC-1 as described in Methods. B) Cell lysates from cultured stable clones indicated
were subjected to Western blot analysis for human podoplanin and subsequently to re-probing for b-actin. Exogenous podoplanin expression
was confirmed (V1 and V2, control stable clones 1 and 2 with empty vector; P4 and P15, stable clones 4 and 15 with podoplanin cDNA-inserted
vector) C) The growth activity of each established clone indicated was examined as described in Methods. (N.S., no significant change versus V1).
D) Migratory activities of each established clone were examined as described in Methods. No significant change in migratory activity was
evident among EBC1 clones (N.S. versus V1). E) The phase contrast image of each cultured clone is shown. F) Cell lysates from the cultured
stable clones indicated were subjected to Western blot analysis for phosphorylated ERM (p-ERM) molecules (p-Ezrin/Radixin and p-Moesin,
arrows) and subsequently to re-probing for total ERM (Ezrin/Radixin and Moesin, arrowheads) and b-actin.
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Page 3 of 15(Figure 1E). The morphological appearances were sup-
ported by the results of Western blot analysis, which
demonstrated that the phosphorylated levels of ERM
molecules (ezrin/radixin/moesin), which are implicated in
cellular actin cytoskeleton rearrangement, were not
affected by podoplanin overexpression in EBC-1 cells (Fig-
ure 1F). These findings except for the proliferation data
are not consistent with those in previous reports [27], in
which podoplanin could lead to enhanced migration activ-
ity and to inducement of filopodia-like formation based on
remodeling of actin cytoskeleton.
Podoplanin attenuates lymphogenous metastatic
potential in vivo
Next, we examined the effect of podoplanin on the
tumor growth and lymphogenous metastatic potential
using a tumor implantation model as described in
Methods. As a result, the growth activity of EBC1-
P-derived tumors showed no significant difference com-
pared to that of EBC1-V-derived tumors (Figure 2A). By
contrast, EBC1-P cell-implanted mice exhibited a signifi-
cantly and markedly reduced incidence of axillary lymph
node metastasis compared to EBC1-V1 cell-implanted
mice (Figure 2B). A representative lymph node specimen
i ss h o w ni nF i g u r e2 C .T h e s er e s u l t ss u g g e s t e dt h a t
podoplanin could help to reduce the potential of lym-
phogenous metastasis of LSCCs.
Podoplanin inhibits tumor-associated lymphangiogenesis
but not angiogenesis
We hypothesized that the reduced potential of lym-
phogenous metastasis in EBC1-Ps was due to podopla-
nin-mediated inhibition of tumor-associated
lymphangiogenesis. To validate our hypothesis, we
Figure 2 Suppressive effect of tumor cell-associated podoplanin on lymph node metastasis in our animal model.A )T h et i m e -
dependent tumor volume derived from each established clone in a tumor implantation model was measured and evaluated as described in
Methods. (N.S. versus V1). B) The incidence of lymph node metastasis of each group was evaluated as described in Methods (**p < 0.001 versus
V1, *p < 0.05 versus V1, N.S. versus V1). C) Representative metastatic foci in axillary lymph nodes of mice with implanted tumors are indicated
(arrows).
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Page 4 of 15performed an immunohistochemical study for blood
and lymphatic vessels, using sections of implanted
tumor tissues. First, we confirmed exogenous podopla-
nin expression in tumor tissue. As shown in Figure
3A, human podoplanin expression was immunohisto-
chemically detected at the tumor cell surface in
EBC1-P4-derived tumor tissue. Next, we evaluated
tumor-associated lymphangiogenesis as described in
Methods. Representative results of immunohistochem-
ical staining for LYVE-1 are shown in Figure 3B. As
evidenced by Figure 3B, many various-sized tumor cell
nests circumscribed with the LYVE-1-positive brown
signal were observed in EBC1-V1-derived tumor tissue
(Figure 3B, EBC1-V1/LYVE-1, arrows). Since we had
never seen such a LYVE-1-positive staining pattern, we
used the alternative lymphatic endothelial marker
podoplanin to perform an additional immunohisto-
chemical examination to ma k es u r et h eL Y V E - 1 - p o s i -
tive brown signal was truly derived from lymphatic
endothelial cells. As a result, we confirmed that mouse
podoplanin had a staining pattern similar to that of
LYVE-1, indicating that the tumor cell nests were cir-
cumscribed with lymphatic endothelial cells (additional
f i l e2 ) .I na d d i t i o n ,t od e t e r m i n ew h e t h e ro rn o tt h e
tumor cell nests circumscribed with LYVE-1-positive
lymphatic endothelial cells are in dilated lymphatic
vessels, we performed Masson staining to visualize
tumor-associated fibrous stroma. As shown in Figure
3C, no stromal component was revealed in tumor cell
nests circumscribed with LIVE-1-positive endothelial
cells with Masson staining, whereas the surrounding
tumor tissue apparently showed Masson-staining-posi-
tive fibrous stroma, indicating that tumor cell nests
were present in the dilated lymphatic vessels. This
immunohistochemical evidence suggested that EBC-1
cells strongly possessed the ability to induce lymphan-
giogenesis and permeate lymphatic vessels, frequently
with the result of lymphogenous metastasis. In accord
with the lymphangiogenic character of EBC1 cell-
derived tumor, we evaluated lymphangiogenic states,
using several indexes including the vessel area and
perimeter. The area and perimeter of LYVE-1-positive
lymphatic vessels in viable tumor tissue were signifi-
cantly lower in EBC1-P-derived tumors than in EBC1-
V-derived tumors (Figure 3D). Surprisingly, the num-
ber of lymphatic vessels showed no significant differ-
ence (Figure 3D). We further evaluated blood
angiogenic states. Blood vessels were immunohisto-
chemically identified as CD31-positive vessels (Figure
4A), and were evaluated with the same indexes as in
the case of lymphangiogenesis. The results showed that
blood vessels were not significantly different for any
indexes (Figure 4B). These histological findings suggest
that podoplanin in LSCCs contributed to the inhibition
of tumor-associated lymphangiogenesis.
Podoplanin suppresses endogenous VEGF-C but not other
lymphangiogenesis-related growth factor gene
expressions in vivo and in vitro
To clarify the mechanisms by which tumor-associated
lymphangiogenesis was suppressed in EBC1-P-derived
tumor tissues, we examined the expression levels of pro-
ven pro-lymphangiogenic growth factors [7-9,13,15,16].
In our previous study, we reported that VEGF-A and
VEGF-C mRNAs are apparently detectable by RT-PCR in
wild-type EBC-1 cells. By contrast, the mRNA expres-
sions of PDGF-B, VEGF-D, Angiopoietin (Ang)-2 and
HGF were weak or undetectable [38]. Therefore, we
quantitatively examined the expression levels of VEGF-A
and VEGF-C in each clone in vitro. Real-time RT-PCR
revealed that the expression levels of VEGF-C mRNA but
not of VEGF-A were significantly reduced in EBC1-Ps
compared to those in EBC1-Vs under culture conditions
(Figure 5A). In addition, PDGF-B mRNA expression was
weak but quantitatively able to be detected by real-time
RT-PCR and showed no significant change among the
clones (Figure 5A). Consistent with the gene expression
pattern, the ELISA assay revealed that VEGF-C but not
VEGF-A content in culture media was significantly
reduced in EBC1-Ps, and that PDGF-BB content was
undetectable (additional file 3). The expression levels of
VEGF-D, Ang-2 and HGF were extremely weak or unde-
tectable in each clone as well as in wild-type EBC-1 cells
(Figure 5B). Next, we examined the EBC1 cell-derived
mRNA levels of human VEGF-A, VEGF-C and PDGF-B
in implanted tumor tissues as described in Methods.
Real-time RT-PCR (Figure 5C) and RT-PCR (Figure 5D)
using human specific primer sets revealed similar results
compared to those from the in vitro experiments. We
further examined the gene expression level of EBC1-
derived human VEGF-C compared to that of mouse
VEGF-C in implanted tumor tissue. As shown in Figure
5E, the human mRNA level was dramatically higher than
the mouse mRNA level, suggesting that the level of
EBC1-derived VEGF-C is predominant compared to that
of host VEGF-C in the implanted tumor tissues. These
findings may be insufficient to determine the significance
of VEGF-C for inducing tumor lymphangiogenesis in our
animal model; however, VEGF-C expression in EBC-1
cells is thought to be a key factor to induce tumor-asso-
ciated lymphangiogenesis, and podoplanin-mediated
downregulation of the VEGF-C gene might be a possible
mechanism underlying the different levels of lymphan-
giogenic activity between EBC1-Vs and EBC1-Ps.
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Page 5 of 15Figure 3 Suppressive effect of tumor cell-associated podoplanin on tumor lymphangiogenesis. A) Immunohistochemical staining for
human podoplanin with EBC1-P4-derived tumor sections. Representative results are indicated. Right photograph is a magnification of the box
shown in the left photograph. Podoplanin expression was observed at the cell surface (arrows). B) Implanted tumor tissues were subjected to HE
staining and immunohistochemical staining for mouse LYVE-1. Representative photographs (for EBC1-V1 and EBC1-P4) are indicated. LYVE-1-
positive signals (arrows) were observed. C) Serially sectioned tumor tissues derived from EBC1-V1 were subjected to immunohistochemical
staining for mouse LYVE-1 (upper photograph) and to Masson staining (lower photograph). Tumor cell nests surrounded by podoplanin-positive
lines (arrows) showed a negative reaction to Masson staining (arrowheads). D) The area, the perimeter, and the number of LYVE-1-positive
lymphatic vessels were measured and evaluated as described in Methods (n = 3 each, *p < 0.001 versus V1).
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Page 6 of 15Podoplanin-induced VEGF-C downregulation is mediated
by an increase in the level of activated JNK in LSCCs
To identify the critical intracellular signal transductions
by which podoplanin inhibited VEGF-C expression in
EBC-1 cells, we examined the effects of intracellular sig-
nal inhibitors related to podoplanin-mediated down-
stream signals on VEGF-C expression. Recent studies
have demonstrated that podoplanin is involved in intra-
cellular signals of the Rho family composed of RhoA,
Rac-1, and cdc42 [27,29,39]. Therefore, we focused on
the relationships among podoplanin, Rho family-
mediated downstream signaling molecules, ROCK/Rho
kinase and JNK, and VEGF-C. Real-time RT-PCR
revealed that the VEGF-C gene expression level in
EBC1-Ps treated with sp600125, a JNK inhibitor, was
significantly improved, nearly to the level found in
EBC1-Vs (Figure 6A), whereas no change in the VEGF-
C expression was observed in EBC1-Ps treated with the
ROCK inhibitor Y-27632 (data not shown). Western
blot analysis revealed that EBC1-Ps had higher JNK
phosphorylation levels than EBC1-Vs, and sp600125-
treated EBC1-Ps showed similar levels of phosphorylated
JNK as in EBC1-Vs (Figure 6B). To further validate
whether the increased activation of JNK-mediated
downregulation of VEGF-C is dependent on podoplanin,
the levels of phosphorylated JNK and VEGF-C mRNA
were examined using siRNA methods. As a result, sig-
nificant upregulation of VEGF-C mRNA (Figure 6C)
and a decreased level of phosphorylated JNK (Figure
6D) were induced in EBC1-P4 cells treated with siRNA-
podoplanin. Taken together, these findings suggested
that the podoplanin-mediated increase in the level of
Figure 4 No significant effect of tumor cell-associated podolanin on tumor angiogenesis. A) Implanted tumor tissues were subjected to
immunohistochemical staining for mouse CD31 using serial sections as described in Methods. Representative photographs (for EBC1-V1 and
EBC1-P4) are indicated. CD31-positive vessels were observed (arrows). B) The area, the perimeter, and the number of CD31-positive vessels were
measured and evaluated as described in Methods (N.S. versus V1).
Suzuki et al. Molecular Cancer 2010, 9:287
http://www.molecular-cancer.com/content/9/1/287
Page 7 of 15Figure 5 Comparison of expression levels of lymphangiogenesis-related factors among the clones. A) Each clone cultured was subjected
to real-time RT-PCR for indicated factors. (n = 3 each, *p < 0.01 versus V1, **p < 0.001 versus V1, N.S. versus V1, # undetectable). B) Each clone
cultured was subjected to RT-PCR for indicated growth factors. PCR primer sets are listed in additional file 4. cDNA templates from HMVEC and
MRC5 were simultaneously amplified as positive controls. C) Each clone-derived tumor tissue was subjected to real-time RT-PCR for indicated
human (h) growth factors using the human gene-specific primer sets listed in the additional file 4. (n = 3, *p < 0.001 versus V1, N.S. versus V1).
D) Each clone-derived tumor tissue was subjected to RT-PCR for indicated human (h) growth factors using the human gene-specific primer sets
listed in the additional file 3. cDNA templates from HMVEC and MRC5 were simultaneously amplified as positive controls. E) Tumor tissues
derived from established clones (EBC1-V1, -V2, -P4, and -P15; n = 3 each) were subjected to real-time RT-PCR for human or mouse VEGF-C using
the species-specific primer sets listed in the additional file 4. Plasmid templates inserting a part of human or mouse VEGF-C gene were prepared
for standard curves as described in Methods. From the obtained data, the number of each template in the tumor-derived cDNA library was
determined. The human VEGF-C mRNA level was expressed as a relative fold increase compared to that of the mouse VEGF-C level. Horizontal
bar means average score.
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Page 8 of 15Figure 6 Podoplanin-dependent VEGF-C downregulation is required for JNK activity. A) Following 24-hour cultivation of each clone under
serum-free conditions, the medium was replaced with fresh serum-free medium containing JNK inhibitor, sp600125 (SP, 20 μM), or a negative
control regent (NC, 20 μM) and incubated for 6 hours. Treated cells were harvested, and subjected to real-time RT-PCR for VEGF-C and GAPDH.
The VEGF-C mRNA level normalized with each GAPDH level was expressed as a relative fold increase compared to that in EBC1-V1 (n = 3 each,
*p < 0.05, **p < 0.005). B) After the same treatment as described in A, the cells were harvested and subjected to Western blot analysis for
phospho-JNK and subsequently to re-probing for total JNK and then to b-actin. Two isoforms of JNK with different molecular weights, JNK1
(p46) and JNK2 (p54) were detected (arrows). C) SiRNA for human podoplanin and negative control oligonucleotides (siRNA podo. and siRNA
cont., respectively) were transfected to EBC1-P4 cells as described in Methods. Twenty-four hours after transfection, the medium was replaced
with serum-free fresh medium. Twenty-four hours later, cells were harvested and subjected to real-time RT-PCR for human podoplanin, VEGF-C,
and GAPDH. Podoplanin and VEGF-C mRNA levels were normalized with the GAPDH level and expressed as relative fold increases compared to
those of the control group (n = 3 each, *p < 0.05, **p < 0.0001). D) Following similar treatments of siRNA to those described in C, the medium
was replaced with serum-free fresh medium. Six hours later, cells were harvested and subjected to Western blot analysis for phosphorylated JNK
and subsequent re-probing for total JNK and b-actin.
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Page 9 of 15activated JNK was a downregulation signal for the
VEGF-C gene in EBC-1 cells. To enhance the credibility
and universality of the podoplanin-JNK-VEGF-C axis in
LSCCs, we further performed in vitro examinations,
using H157, a lung SCC cell line with podoplanin
expression (Figure 1A). Consistent with the results
shown in Figure 6, VEGF-C gene expression and protein
secretion were significantly upregulated in H157 cells
treated with the JNK inhibitor sp600125 (Figure 7A). In
addition, significant upregulation of VEGF-C mRNA
(Figure 7B) and a decreased level of phosphorylated JNK
(Figure 7C) were also induced in H157 cells treated with
siRNA-podoplanin. On the contrary, we previously
reported the intracellular signaling pathways, p42/44
MAPK and p38 MAPK, by which the VEGF-C gene is
stimulated in the oral SCC cell line [38]. Although a 20
μM concentration of sp600125 reportedly had no influ-
ence on p42/44 MAPK and p38 MAPK activities in cul-
tured cells [40], we confirmed the effect of sp600125 on
the phosphorylation levels of p42/44 MAPK and p38
Figure 7 Podoplanin-JNK-VEGF-C axis in H157 cells. A) Experiments similar to those described in Figure 6A were performed using H157.
VEGF-C mRNA level (left graph) and VEGF-C content (right graph) in the culture media were assessed by real-time RT-PCR and ELISA,
respectively, as described in Methods. For the ELISA, culture media were harvested twenty-four hours after treatment with inhibitor (n = 3 each,
*p < 0.05). B) Similar experiments described in Figure 6C were performed using H157 (n = 3 each, *p < 0.05, **p < 0.0001). C) Similar
experiments described in Figure 6D were performed using H157 cells. Each band intensity was measured as described in Methods, and the level
of phosphorylated JNK1 (p-JNK1) or p-JNK2 was normalized with each total JNK level, and expressed as a relative fold increase compared to the
control. (n = 3 each, *p < 0.05 versus siRNA cont., **p < 0.01 versus siRNA cont.).
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Page 10 of 15MAPK in EBC-1 and H157 cells. Consistent with the
previous report [40], the phosphorylation levels of these
molecules were hardly affected by sp600125 treatment
at a 20 μM concentration in these cells (data not
shown). Taken together, these findings suggest that JNK
is a key pathway for inducing podoplanin-mediated
downregulation of the VEGF-C gene in LSCCs.
Discussion
Using stable lung SCC cell line-derived transformants
exogenously expressing podoplanin, we herein found
direct evidence suggesting the role of podoplanin in
experimental tumor progression. The body of our find-
ings is that podoplanin in LSCCs can induce VEGF-C
downregulation via the JNK signaling pathway(s), and
can impair tumor-associated lymphangiogenesis and
lymphogenous metastasis
Current immunohistochemical studies have revealed the
expression of podoplanin in a variety of malignant cells. In
the case of SCCs, podoplanin is mainly expressed in per-
ipheral cancer cells in solid nests [22,34,36]. A series of
these past studies relevant to tumor cell-associated podo-
planin suggest its role in promoting cancer progression,
especially in enhancing the potential of cancer cell inva-
sion, and this hypothesis has been supported by several
past studies [41]. Indeed, previous reports have shown
experimental evidence of interesting and important cyto-
physiological and cytochemical phenomena mediated by
podoplanin. Notably, as evidenced by previous studies,
podoplanin does not exert the same function in all cell
types. For example, although podoplanin can induce RhoA
activation and an epithelial-mesenchymal transition
(EMT) in MDCK cells [29], it attenuated RhoA activity
and could not induce EMT in a breast carcinoma cell line
[27], suggesting that podoplanin exerts cell type-specific
functions. Therefore, we are concerned about the interpre-
tation of podoplanin’s functions in several past studies. In
fact, the function-related data were often from experi-
ments using malignant cell lines that lacked podoplanin
expression in actual human lesions. For example, since it
has been immunohistochemically reported that almost all
adenocarcinomas cells, including lung cancer, hardly
express podoplanin [22,23], the evidence from experimen-
tal studies on podoplanin functions using such cell lines/
animal models may be rather different from the pathophy-
siological roles it plays in human malignancies. Conse-
quently, experimental studies should be designed with
human cell lines that actually express podoplanin in
human malignancies in order to understand its true role
in human pathology. In the present study with lung SCC
cell line EBC-1, several different results relating to podo-
planin functions were observed compared to those
reported in past studies: 1) podoplanin did not promote
cell migration, and 2) podoplanin-mediated morphological
change, such as filopodia-like formation, was not observed.
These findings should be interpreted as relating only to
LSCC-associated podoplanin function.
We have previously reported that VEGF-C expression
is positively regulated by p42/44 MAPK, protein kinase
C (PKC) or p38 MAPK in oral squamoid cancer cells
[38]. In contrast, a negative regulatory mechanism has
not been reported in any past studies. Here, we found
the critical intracellular signaling pathway, JNK, for the
negative regulation of VEGF-C gene. A decreased level
of phosphorylated JNK but not of total JNK was induced
by siRNA-mediated podoplanin knockdown (Figures 6D
and 7C), suggesting that podoplanin could induce JNK
phosphorylation. By contrast, as shown in Figure 6B,
not only the phosphorylated JNK but also the total JNK
levels were apparently increased in stable transformants
exogenously expressing podoplanin. These phenomena
may be due to the podoplanin-dependent phenotypic
change of EBC-1 cells. As described above, podoplanin
has the potential to induce EMT [29], so forced and
long-term expression of podoplanin in our experimental
conditions may cause several phenotypic changes of
EBC-1 cells, resulting in the increased level of total JNK.
Taken together, podoplanin-dependent downregulation
of VEGF-C is mediated by the direct and/or indirect
increase of active JNK level in LSCCs.
EBC1-induced lymphatic vessels in the implanted
tumor were markedly dilated, frequently resulting in
lymph node metastasis. In this model, podoplanin nar-
rowed lymphatic vessels in luminal size. Since VEGF-C
is reportedly an inducer not only in proliferation/migra-
tion of lymphatic endothelial cells but also in the enlar-
gement of lymphatic vessels [42], podoplanin-mediated
dowregulation of VEGF-C is a consistent mechanism for
the decreased area and perimeter of lymphatic vessels.
By contrast, the reason why podoplanin-mediated dow-
regulation of VEGF-C has no influence on the lymphatic
vessel density remains unclear. Inoculated EBC-1 cells
might be able to permeate the existing lymphatic vessels
in an early phase of tumor growth and gradually prolif-
erate in solid nests in lymphatic vessels. As a conse-
quence, intralymphatic EBC-1 cell-derived VEGF-C acts
on the free surface of lymphatic endothelial cells,
thereby impairing concentration gradient-dependent
vessel migration/sprouting but not affecting vessel pro-
liferation/enlargement in our animal model.
Considering that a positive correlation between tumor
VEGF-C and tumor lymphangiogenesis/lymphogenous
metastasis has been reported in numerous malignancies
including non-small cell lung carcinoma [5], we herein
found a novel molecular mechanism, the podoplanin-
JNK-VEGF-C axis, by which podoplanin impaired lym-
phogenous metastasis in our animal model. We could
not, however, demonstrate any direct evidence
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VEGF-C axis and the podoplanin-dependent impairment
of lymphangiogenesis/lymphogenous metastasis. There-
fore, further examination is necessary to clarify the
mechanism by which podoplanin suppresses lymph
node metastasis, including the possibility that podopla-
nin is critical in other lymphangiogenesis-independent
steps to achieve lymph node metastasis.
Conclusions
All together, the findings obtained from our animal
model in the present study were experimentally able to
support recent clinicopathological evidence suggesting
that the expression of podoplanin in cancer cells is a
favorable prognostic marker of patients with lung SCC.
Moreover, the podoplanin-mediated downregulation of
the VEGF-C gene via JNK (the podoplanin-JNK-VEGF-
C axis) was newly found as one of the possible underly-
ing mechanisms. Therefore, podoplanin may be a useful
prognostic biomarker to determine the malignancy of
lung SCC. Further advanced study to understand the
pathophysiological functions of podoplanin, including
the podoplanin-mediated decreased potential for lymph
node metastasis in cancer cells, would provide beneficial
information to explore a novel therapeutic strategy for
patients with lung SCC.
Methods
Cells and Reagents
The lung squamoid cancer cell lines EBC-1 and H157
were maintained with RPMI 1640 (Sigma-Aldrich Japan,
Tokyo, Japan) supplemented with 100 units/mL penicil-
lin/streptomycin and 10% fetal bovine serum (FBS).
H u m a nf i b r o b l a s t( M R C 5 )a n dm o u s ef i b r o b l a s t
(NIH3T3) were purchased from the American Type
Culture Collection and maintained with Dulbecco’s
Modified Eagle’s Medium supplemented with 10% FBS.
Human microvascular endothelial cells (HMVECs) were
p u r c h a s e df r o mK u r a b oC o .L t d . ,T o k y o ,J a p a n ,a n d
maintained with EGM2 medium (Kurabo). c-Jun N-
terminal kinase (JNK) inhibitor sp600125 and ROCK/
Rho kinase inhibitor Y-27632 were purchased from Pro-
mega K.K., Tokyo, Japan. Anti-human podoplanin
mouse monoclonal antibody was purchased from Angio-
B i oC o . ,D e lM a r ,C A .A n t i - t o t a lJ N K ,a n t i - p h o s p h o -
JNK, anti-phospho-ERM and anti-total ERM were pur-
chased from Cell Signaling Technology, Beverly, MA.
Anti-b-actin rabbit polyclonal antibody was purchased
from Sigma-Aldrich Japan, Tokyo, Japan. Anti-murine
lymphatic vessel endothelial hyaluronan receptor-1
(LYVE-1) rabbit polyclonal antibody was produced in
our laboratory as described previously [38], and anti-
mouse CD31 rabbit polyclonal antibody was purchased
from Abcam Inc., Cambridge, MA.
Animals
Male BALB/c nu/nu mice (5 weeks old) were from
Kyudo Co., Ltd. (Tosu, Saga, Japan). All animal experi-
ments were done under approved protocols and in
accordance with recommendations for the proper care
and use of laboratory animals by the Committee for
Animal, Recombinant DNA, and Infectious Pathogen
Experiments at Kyushu University and according to the
Law (No. 105) and Notification (No. 6) of the Japanese
Government.
Reverse transcription polymerase chain reaction (RT-PCR)
and real-time RT-PCR
Total cellular RNA was extracted from culture cells or
implanted tumor tissues with the ISOGEN system
(Wako Pure Chemical Industries, Osaka, Japan) accord-
ing to the manufacturer’s instructions, and treated with
RNase-free DNase I (Behringer Roche Applied Science
Japan, Tokyo, Japan). Subsequently, aliquots (25 ng) of
total RNA were reverse-transcribed and used for PCR
templates. Real-time RT-PCR was performed for quanti-
fication of gene expression levels. Amplification of target
genes was monitored in real-time, and gene expression
levels were quantified using the Sequence Detection Sys-
tem, model 7000 (Applied Biosystems Ltd., Tokyo,
Japan), according to the manufacturer’si n s t r u c t i o n sf o r
TaqMan methods. The oligonucleotide sequences of
PCR primer sets and TaqMan probes were listed in
additional file 4. The target gene expression level was
normalized with GAPDH level and expressed as relative
fold increases compared to mean level in control group.
Construction of plasmid vector and plasmid templates
The PCR primers incorporating Hind-III and Xho-I sites
for amplification of human podoplanin are as follows: 5’-
GATGTGGAAGGTGTCAGCTC-3’(forward) and 5’-
GATCCTCGATGCGAATGCCT-3’ (reverse). A PCR
amplicon using cDNA from HMVECs was inserted into a
plasmid vector, pCEP4, for mammalian cell expression
according to general subcloning methods. The primer
sequences for construction of plasmid templates are as fol-
lows: human and mouse vegf-c,5 ’-GAAATTACAGTGCC
TCTCTC-3’ (forward) and 5’-CTAGTTCTTTGTGGGTC-
CAC-3’ (reverse). Each PCR amplicon using cDNA from
MRC5 or NIH3T3 was inserted into a plasmid with a
pCRII TA cloning kit (Invitrogen, Carlsbad, CA), according
to the manufacturer’s instructions. The sequence of the
insert was examined using the CEQ 2000 Sequence Detec-
tion System (Beckman Coulter, Inc., Fullerton, CA), and
complete matching was confirmed through comparison to
those reported in GenBank (accession nos. AF 390106,
NM 005429, and NM 009506 for human podoplanin,
human vegf-c,a n dm o u s evegf-c, respectively) was
confirmed.
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Constructed pCEP-4 inserted human podoplanin cDNA
and empty pCEP-4 were transfected into EBC-1 cells
using LipofectAMINE 2000 (LF2000) reagent (Invitro-
gen) according to the manufacturer’s instructions. Forty-
eight hours after transfection, the culture medium was
replaced with medium containing 400 μg/mL hygromy-
sin (RPMI-hygro). At that concentration, wild EBC-1
cells were completely killed. The cells were then main-
tained with RPMI-hygro until the selected cells had
grown appropriately. Next, the selected cells were spread
onto 96-multiwell plates for single-cell culture and were
maintained with RPMI-hygro until they reached conflu-
ence. Single-cell-derived confluent cells were continu-
ously maintained in RPMI-hygro in larger shares.
Tumor implantation model
Under sufficient anesthesia by an i.p. injection of sodium
pentobarbital, 1 × 10
6 of EBC1-V1, EBC1-V2, EBC1-P4,
and EBC1-P15 cells were subcutaneously injected into
the dorsal region. After inoculation, tumor length and
width were measured every 3 days for 3 weeks, and
tumor volume was estimated by the formula V = π/6 ×
a
2 × b, where a was the short axis and b the long [43]. 21
days after implantation, mice were sacrificed and the pri-
mary tumors and axillary lymph nodes (two lymph nodes
per mouse) were harvested. Each harvested primary
tumor tissue was sliced in two, and the slices were used
as samples for histological and molecular biological
experiments. Harvested axillary lymph nodes were sub-
jected to HE staining. Through microscopic findings,
metastatic status was divided into two cases–positive and
negative–irrespective of the area of metastatic foci. The
positive lymph nodes were counted, and the incidence of
metastasis was expressed as the ratio of positive lymph
nodes to the total number of lymph nodes in each group.
Western blot analysis
Cells were lysed with 200 ml of cell lysis buffer (Promega)
containing a cocktail of protease inhibitors (Nacalai Tes-
que), and the supernatant of the lysed cells was recov-
ered. An aliquot of 20 mg of proteins was subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) under reducing condition, and were
then transferred to a PVDF membrane. An hour after
being blocked with PBS containing 5% non-fat milk, the
membrane was incubated overnight, with each primary
antibody diluted with PBS containing 5% BSA and 0.1%
Tween 20, at 4°C. The dilution rate was determined
according to the manufacturer’s instructions. Following
several washings with PBS containing 0.1% Tween 20,
the membrane was treated for 2 hours with an appropri-
ate HRP-labeled secondary antibody, HistoFine (DAKO,
Glostrup, Denmark) at room temperature. The target
proteins were visualized by a luminal chemiluminescent
reagent, LumiGLO (Cell Signaling Technology). After
that, the membrane was subjected to re-probing assay.
Briefly, following stripping the binding antibodies using
Stripping Solution (Nacalai Tesque, Kyoto Japan) accord-
ing to the manufacture’s instruction, the membrane was
washed with PBS and subjected to the WB described
above. The band intensity was measured with FMBIO
(Hitachi Software Engineering Co. Ltd., Tokyo, Japan).
In vitro proliferation assay
The WST-8 assay kit (Nacalai Tesque) was used to deter-
mine the proliferation rates of EBC1-Vs cells and EBC1-Ps
cells, which were seeded at 1 × 10
3 cells/well on 96-well
plates (n = 12 each). Cell viability was evaluated every day
for 3 days according to the distributor’sp r o t o c o l .T h e
obtained data were expressed as relative fold increases of
O.D. values compared to those 1 day after dissemination.
Migration assay
Boyden chamber cell invasion was assayed using a cell
culture-chamber-insert system (BD, FALCON) with an
8 μm polyethylene terephthalate (PET) membrane. First,
1×1 0
5 cells were seeded on the upper chamber in
RPMI medium with 1% FBS. The RPMI medium with
1% or 10% FBS was added to the lower chamber. After
18 hours, cells that did not cross the membrane were
scraped off the upper side of the membrane with a cot-
ton swab. Cells that had transmigrated to the lower side
w e r ef i x e dw i t h7 0 %e t h a n o la n ds u b j e c t e dt oG i e m s a
staining. The membrane was excised from its support
and mounted on a glass slide. Migrating cells in four
independent microscopic visual fields (×100) were
counted, and expressed as mean number per one field.
Immunohistochemistry
Angiogenesis and lymphangiogenesis in implanted
tumor tissue were immunohistochemically evaluated.
Detail immunohistochemcial procedures were described
previously [38]. The lymphatic vessels and blood vessels
were identified as LYVE-1-positive and CD31-positive
vessels, respectively. Image J Software was used to count
the total numbers and measure the areas and perimeters
of vessels whose apparent luminal areas were framed by
LYVE-1-positive or CD31-positive endothelial cells in
viable tumors. The blood and lymphatic vessel number
was expressed as that per unit of viable tumor area, and
the vessel area was expressed as that per a vessel. All
sections were independently evaluated by three persons
(K.S., M.O., H.S.).
siRNA transfection
Human podoplanin siRNA was purchased from Invitro-
gen. The RNA sequence is as below; 5’-UAUAGCGGUCU
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Duplex (Invitrogen) was used as a negative control. siRNA
transfection was performed with lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assay (ELISA)
VEGF-C content in the culture media was measured
using Quantikine Immunoassay systems for human
VEGF-C (R&D Systems) according to the manufac-
turer’s instructions. Three independent experiments
were performed and the obtained data were statistically
analyzed. VEGF-C content in the culture media was
expressed as the amount of protein secreted from
100,000 cells during 24 hours.
Statistical analysis
All data were expressed as means ± SD and were ana-
lyzed by one-way ANOVA with Fisher’s adjustment. Sta-
tistical significance was determined using the log-rank
test, and p < 0.05 was considered statistically significant.
Statistical analysis was done using SPSS software version
9.0 (SPSS, Chicago, IL).
Additional material
Additional file 1: Podoplanin-mediated promotion of the migration
activity of oral squamoid cancer cells. Methods, results (graphs) and
legends of an in vitro proliferation assay and a migration assay are
provided.
Additional file 2: A similar immunohistochemical staining pattern
between mouse LYVE-1-positive and mouse podoplanin-positive
vessels in an implanted tumor tissue. Methods, results (photographs)
and legends of immunohistochemical studies were shown.
Additional file 3: The podoplanin-mediated reduction of VEGF-C
secretion but not of VEGF-A secretion in EBC1 cells in vitro.
Methods, results (graphs) and legends of Enzyme-linked immunosorbent
assay (ELISA) were shown.
Additional file 4: Information of primer sets and TaqMan probes for
human specific and mouse specific real-time RT-PCR and semi-
quantitative RT-PCR. A table listing oligonucleotide sequences of PCR
primer sets and TaqMan probes, and legends were shown.
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